Rigel Pharmaceuticals(RIGL)
SOUTH SAN FRANCISCO, CAPharmaceutical
Focus: Rigel is a public specialty pharmaceutical company focused on small-molecule therapeutics for immunology, hematology, and oncology. With $117M in FY2025 revenue, it is a mid-cap biotech dependent on a narrow commercial portfolio.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Rigel Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Rigel Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$117M
Key Products
Help build intelligence for Rigel Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.